Stock Market News Stock Market News
  • Dow
  • S&P
  • Nasdaq
  • Stocks
  • ETFs
  • Bonds
  • Commodities
  • Earnings
  • Dividends
  • REITs
  • IPOs
  • Crypto
  • Forex
  • Tech
  • Politics
  • +

2 months AbbVie Stock Rises After Leerink Partners Upgrades Its Rating Zacks

Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.

AbbVie (ABBV)

  X     

17 hours AbbVie’s Stock Is Unfairly Cheap Seeking Alpha

   X     

1 day Opinion on my current portfolio Reddit

   X     

2 days AbbVie (ABBV) Stock Moves -0.32%: What You Should Know Zacks

   X     

3 days Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report? Zacks

   X     

3 days AbbVie cuts 2024 profit forecast on acquisition expenses Investing.com

   X     

1 week The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer Zacks

   X     

1 week AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks

   X     

1 week Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet Zacks

   X     

1 week AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It Zacks

   X     

2 weeks AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing Zacks

   X     

3 weeks Pharma Stock Roundup: PFE’s 2025 Outlook, MRK & ABBV’s M&A Deals Zacks

   X     

3 weeks Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know Zacks

   X     

3 weeks AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? Investor's Business Daily

   X     

3 weeks AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors Zacks

   X     

3 weeks AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors Seeking Alpha

   X     

4 weeks ABBV’s Acquisition Spree Continues: Buy, Sell or Hold the Stock? Zacks

   X     

4 weeks ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline Zacks

   X     

4 weeks Betting Big On AbbVie: A Prescription For Growth And Dividends Seeking Alpha

   X     

1 month AbbVie’s Recently Acquired Parkinson’s Drug Meets Third Study Goal Zacks

   X     

1 month The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group Zacks

   X     

1 month Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences Zacks

   X     

1 month AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025 MarketWatch

   X     

1 month AbbVie reports positive results in Parkinson’s trial Investing.com

   X     

1 month Calls of the Day: Toast, Abbvie, Berkshire Hathaway YouTube

   X     

1 month AbbVie Inc. (ABBV) Citi’s 2024 Global Healthcare Conference (Transcript) Seeking Alpha

   X     

1 month Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock Zacks

   X     

1 month Why Dividend Aristocrats Like Walmart, ADP, and AbbVie Are Set to Outperform Yahoo Finance

   X     

1 month Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report? Zacks

   X     

2 months Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead Seeking Alpha

   X     

2 months AbbVie: Upgrading To ‘Strong Buy’ After Pullback Seeking Alpha

   X     

2 months Trade Tracker: Jim Lebenthal buys more Abbvie YouTube

   X     

2 months AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback Investor's Business Daily

   X     

2 months AbbVie, Nvidia Lead Friday’s Market Cap Stock Movers Investing.com

   X     

2 months Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? Zacks

   X     

2 months Where Will AbbVie Be in 5 Years? Yahoo Finance

   X     

2 months AbbVie’s Ovarian Cancer Drug Elahere Gets Approval in Europe Zacks

   X     

2 months Dividend King AbbVie Just Paid Investors: Here’s How Much They Got 24/7 Wall St.

   X     

2 months Pharma Stock Roundup: AZN, BAYRY’s Earnings, ABBV’s Pipeline Setback Zacks

   X     

2 months AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? Zacks

   X     

2 months Final Trades: Bitcoin, Abbvie and Baker Hughes YouTube

   X     

2 months Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects Seeking Alpha

   X     

2 months AbbVie’s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio Yahoo Finance

   X     

2 months Final Trades: Lyft, Meta, United States Oil Fund & Abbvie YouTube

   X     

2 months AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings Seeking Alpha

   X     

2 months Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade) Seeking Alpha

   X     

2 months AbbVie Stock: Keep Calm And Buy The Dip Seeking Alpha

   X     

2 months Bristol Rockets 11% As Investors Question AbbVie’s $8.7 Billion ‘Mistake’ Investor's Business Daily

   X     

2 months AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials Yahoo Finance

   X     

2 months RHHBY or ABBV: Which Is the Better Value Stock Right Now? Zacks

   X     

2 months Analyst Report: AbbVie Inc Yahoo Finance

   X     
More news +
Home | Contact
  • X

© 2025 The Stock Market News